Osteoporosis

 

Post Fracture Oversight Persists in Osteoporosis

September 25, 2020

In a review recently published in Current Osteoporosis Reports, Sarah French, M.D., a rheumatologist with the University of California at San Francisco, summarizes performance quality measures for osteoporosis using Centers for Medicare and Medicaid measures for pay-for-performance programs. In this interview, Dr. French shares with us her findings.

Here's Where We Fail (and Succeed) in Osteoporosis Care

September 18, 2020

Today, we talk with Dr. Sarah French, a rheumatologist with the University of California at San Francisco. Dr. French recently published a review in Current Osteoporosis Reports that addresses successes and failures in quality improvement initiatives in osteoporosis. Through the MIPS program, healthcare providers are required to select six quality measures. And while they may be performing well on osteoporosis screenings, their track record on osteoporosis management isn't fairing as well. Dr. French has identified this as an area for improvement. In this interview, she explains how.

Bisphosphonate Use Associated with Increased Fracture Risk

September 16, 2020

Bisphosphonate use, especially for more than five years, is associated with an increased risk of atypical femoral fractures, but this risk falls considerably after discontinuation, according to a Nationwide Danish an analysis and review presented on September 13 at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held virtually.

Teriparatide for Bone Formation in Hip Fractures

September 16, 2020

Teriparatide, a recombinant human parathyroid hormone analog [rhPTH(1-34)] approved for women and men with osteoporosis, has been shown to renew bone tissue in patients with femoral neck fractures of the hip, according to research presented at the American Society for Bone and Mineral Research (ASBMR) annual meeting which was held this week.

Zoledronate As Booster Drug in Fight Against Osteoporosis

September 14, 2020

Some evidence shows the combination of teriparatide and denosumab, followed by a single dose of zoledronate, may be an effective strategy in the long-term management of high-risk fragility fractures.

Abaloparatide Shown to Increase Bone Mineral Density

September 11, 2020

The osteoporosis treatment abaloparatide has been shown to increase bone mineral density of the lumbar spine, total hip and femoral neck bone in patients with osteoporosis who are at high risk for fracture, according to a study presented today at the American Society for Bone and Mineral Research annual meeting which is being held virtually through Tuesday.

Loss of Total Body Lean Mass Linked to Increase Risk of Fractures

September 07, 2020

Patients attempting to lose weight through dietary changes should be advised of the importance of maintaining their existing muscle mass and strength through exercise, so as not to increase their risk of fractures, Canadian researchers say.

Repeat BMD Testing Every Three Years May Hold Little Value

September 07, 2020

Postmenopausal women may not need a repeat bone mineral density test after three years to determine risk of osteoporotic fracture, a study finds.

Smoking Declines Precede Dip in Hip Fractures

September 03, 2020

Hip fractures in the United States and developed countries have been declining for over four decades. But why? Dr. Timothy Bhattacharyya, an orthopedic surgeon and head of Orthopedics Research for the Clinical Trials and Outcomes Branch of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, delved into the root cause of this phenomenon in a study published in July in JAMA Internal Medicine.

Treatment Adherence Still Difficult in Osteoporosis

August 18, 2020

Persistence and adherence to parenteral osteoporosis therapies are suboptimal and worsen with time, a study finds.